Mode
Text Size
Log in / Sign up

Atherogenic Index of Plasma Shows Limited Discrimination for Predicted CVD High-Risk Status in Chinese Screening CohortBlood fat ratio linked to predicted heart disease risk in Chinese screening study

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider AIP as a potential adjunct marker in screening, but recognize its limited standalone discrimination for predicted CVD risk.

This cross-sectional cohort analysis examined 6,702 participants from a community screening program in Luohe, China (median age 58 years; 38% men). The study assessed the association between the atherogenic index of plasma (AIP), calculated as log10(TG/HDL-C), and WHO CVD risk chart-defined predicted 10-year CVD high-risk category (high risk: ≥20%). The predicted high-risk category was present in 1,440 participants (21%).

Higher AIP was non-linearly associated with higher odds of predicted CVD high-risk status. When used alone, AIP showed modest discrimination for this predicted risk category, with an area under the curve (AUC) of 0.557. Discrimination improved in adjusted models (AUC 0.650), and a random forest model achieved an AUC of 0.792.

Safety and tolerability data were not reported. Key limitations include the cross-sectional design, which cannot establish temporality, and the use of a predicted risk category rather than adjudicated or incident CVD events. The outcome represents calculated probability, not actual clinical events.

For practice, this observational evidence suggests AIP may serve as a simple adjunct marker to triage individuals for intensified risk assessment in primary-care screening settings. However, clinicians should recognize that AIP alone has limited discrimination for predicted high-risk status and does not predict actual CVD events. These findings require validation in longitudinal studies with hard clinical endpoints.

Researchers looked at whether a simple blood test calculation, called the atherogenic index of plasma (AIP), could help identify people at high risk for heart disease. They studied 6,702 adults (average age 58) who took part in a community health screening program in China. The AIP is calculated from two common cholesterol measurements: triglycerides and HDL (the 'good' cholesterol).

The study found that people with a higher AIP score were more likely to be in the high-risk category according to a standard World Health Organization heart disease risk chart. However, when used by itself, the AIP score was only moderately good at telling high-risk and low-risk people apart. When combined with other health information in a computer model, the prediction became much better.

It's important to understand what this study did and did not show. Because it was a cross-sectional study—a single snapshot in time—it can only show a link, not prove that a high AIP causes higher risk. Also, the 'outcome' was a predicted risk score, not whether people actually went on to have a heart attack or stroke. No safety issues were reported because this was an analysis of existing test results.

Readers should take away that this research suggests a simple blood calculation might be one helpful piece of information for doctors assessing heart disease risk during check-ups. However, it is not a standalone test and is best used alongside other established risk factors. More research, especially studies that follow people over time to see who develops actual heart problems, is needed.

What this means for you:
A blood fat ratio was linked to predicted heart risk in a study, but it's an early finding that needs more research.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundCommunity screening programs increasingly use World Health Organization (WHO) cardiovascular disease (CVD) risk charts to identify individuals at high predicted 10-year risk. The atherogenic index of plasma (AIP), derived from triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C), may capture atherogenic dyslipidemia and support pragmatic risk stratification.MethodsWe conducted a cross-sectional analysis of baseline data from the China Health Evaluation And risk Reduction through nationwide Teamwork (ChinaHEART) community screening program in Luohe, China. Among 6,860 screened participants, 6,702 with complete data for AIP computation, WHO risk classification, and prespecified covariates were included. The outcome was the WHO CVD risk chart-defined predicted 10-year CVD high-risk category (high risk: ≥20%), rather than adjudicated or incident CVD events. AIP was calculated as log10(TG [mmol/L]/HDL-C [mmol/L]) and modeled as both a continuous and categorical exposure; spline models tested nonlinearity, and ROC analyses evaluated discrimination and derived a Youden-index cutoff. In addition, we performed an explainable machine-learning pipeline for CVD high-risk prediction using LASSO logistic regression for feature selection (AIP forced-in), followed by a random forest classifier and SHAP-based interpretation.ResultsOf 6,860 screened participants, 6,702 were included in the analytic sample (median age 58 years; 38% men). The WHO CVD risk chart-defined predicted 10-year CVD high-risk category was present in 1,440 (21%) participants and was more frequent in the high-AIP group than in the low-AIP group. Higher AIP was associated with higher odds of CVD high-risk status. Restricted cubic splines supported a non-linear association. Discrimination was modest for AIP alone (AUC 0.557) and improved in adjusted models (AUC 0.650). In the machine-learning pipeline (LASSO + random forest), the random forest model achieved an AUC of 0.792, and SHAP analyses ranked LDL-C and history of hypertension as the strongest contributors, with AIP remaining among the top predictive features.ConclusionIn this community-based ChinaHEART population, higher AIP was non-linearly associated with the WHO CVD risk chart-defined predicted 10-year CVD high-risk category. Although AIP alone had limited discrimination, it may serve as a simple adjunct marker to triage individuals for intensified risk assessment in primary-care screening settings.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.